Increasing HPV Vaccination in Pediatric, Adolescent, and Young Adult (PAYA) Cancer Survivors

Launched by MASONIC CANCER CENTER, UNIVERSITY OF MINNESOTA · Dec 19, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on increasing the number of pediatric, adolescent, and young adult cancer survivors who receive the HPV vaccine. The HPV vaccine helps protect against certain cancers caused by the human papillomavirus (HPV). The study aims to encourage these survivors, aged 9 to 26, to start and complete the vaccine series, which consists of three doses.

To participate, you need to be a current patient at specific clinics in Minnesota, either a survivor of childhood cancer or a caregiver of a survivor. You should be at least six months post-treatment and not have received the HPV vaccine before. If you join the trial, you can expect support and guidance throughout the vaccination process. It’s important to know that this study is actively recruiting participants, and your involvement could help improve vaccination rates among young cancer survivors.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Current patient in the University of Minnesota CCSP clinic or the Children's Minnesota Long-Term Follow-up (LTFU) Program clinic.
• • Patients seen in the CCSP clinic who do not have a history of cancer but who have received immunosuppressive therapy or HSCT for treatment of a hematologic disorder.
• • Survivor of childhood cancer (defined as diagnosed with cancer at age 25 years or younger) who is currently 18-26 years of age OR a caregiver of a survivor of childhood cancer who is currently 9-17 years of age.
• • 6+ months post-treatment; current treatment for graft-versus-host disease allowed
• • No previous HPV vaccination or incomplete HPV vaccination (defined as \<3 doses post-cancer therapy). Individuals who are unsure of their HPV vaccination status who are unable to find vaccination records per the procedures detailed in Section 5.2, EHR support will be eligible, in concordance with real-world clinical practice regarding HPV vaccination.
• Exclusion Criteria:
• • Previous completion of the HPV vaccination series. Those who are eligible for re-vaccination per the CDC guidelines will be encouraged by their oncologist to re-vaccinate, but will not be included in the QI study or RCT.
• • Unable to read/write in English per self-report (only applies to participants in the RCT \[Aim 2\]).
• • Pregnant at the time of enrollment or plans to become pregnant in the next year. Pregnancy test at the time of enrollment is not required if pregnancy not clinically suspected in concordance with clinical guidelines for HPV vaccine administration.
• • Currently receiving treatment for cancer or hematologic disorder or plan for treatment within 12 months of enrollment; treatment for graft-versus-host disease allowed.
• • Other contraindications to the HPV vaccine (e.g. history of immediate hypersensitivity reaction to any vaccine component, including yeast).